The Hormonal Profile of Benign Breast Disease

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Nov 22

PMID 23169293

Citations 9

Authors

E Samoli

D Trichopoulos

A Lagiou

P Zourna

C Georgila

P Minaki

A Barbouni

D Vassilarou

A Tsikkinis

C Sfikas

E Spanos

P Lagiou

Affiliations

Soon will be listed here.

Abstract

Background: Limited information exists about the endocrine milieu of benign breast disease (BBD), a documented breast cancer risk factor. We compared blood levels of estrogens, testosterone and insulin-like growth factor-1 (IGF-1) between BBD patients by histological type and women without breast pathology.

Methods: We studied 578 BBD patients and 178 healthy women in Athens, Greece, who provided blood samples, and completed interviewer-administered questionnaires.

Results: Of the BBD patients, 254 had non-proliferative disease, 268 proliferative disease without atypia and 56 atypical hyperplasia. Comparing BBD patients with healthy women, the per cent differences (and 95% confidence intervals) for blood hormones, among pre-menopausal and peri/post-menopausal women, respectively, were: 22.4% (-4.0%, 56.1%) and 32.0% (5.6%, 65.1%) for estradiol; 26.2% (10.1%, 44.8%) and 30.9% (16.8%, 46.6%) for estrone; 19.5% (3.1%, 38.4%) and 16.5% (-5.0%, 42.9%) for testosterone; and -5.2% (-13.8%, 4.4%) and -12.1% (-19.8%, -3.6%) for IGF-1. Steroid hormones tended to be higher in proliferative compared with non-proliferative BBD.

Conclusions: Circulating steroid hormones tend to be higher among women with BBD than women with no breast pathology and higher in proliferative than non-proliferative disease; these patterns are more evident among peri/post-menopausal women. In peri/post-menopausal women IGF-1 was lower among women with BBD compared with healthy women.

Citing Articles

Enhancing the Understanding of Breast Vascularity Through Insights From Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Comprehensive Review.

Sachani P, Dhande R, Parihar P, Kasat P, Bedi G, Pradeep U Cureus. 2024; 16(9):e70226.

PMID: 39463566 PMC: 11512160. DOI: 10.7759/cureus.70226.

TGF-β, IL-1β, IL-6 levels and TGF-β/Smad pathway reactivity regulate the link between allergic diseases, cancer risk, and metabolic dysregulations.

Elkoshi Z Front Immunol. 2024; 15:1371753.

PMID: 38629073 PMC: 11019030. DOI: 10.3389/fimmu.2024.1371753.

Association between breast nodules, anxiety, depression and metabolic risk factors in a Chinese cohort.

Long Y, Zhang W, Zheng M, Xie Q, Liu H, Hu X Front Psychiatry. 2023; 14:944354.

PMID: 37275984 PMC: 10232859. DOI: 10.3389/fpsyt.2023.944354.

Efficacy and Safety of Acupuncture for Cyclic Mastalgia: Study Protocol for a Randomized, Sham-Controlled Trial.

Gao S, Sun Y, Shi H, Fang J, Liu Z Int J Womens Health. 2023; 15:845-855.

PMID: 37275513 PMC: 10237189. DOI: 10.2147/IJWH.S410000.

Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women.

Clendenen T, Ge W, Koenig K, Afanasyeva Y, Agnoli C, Bertone-Johnson E J Clin Endocrinol Metab. 2021; 106(11):e4542-e4553.

PMID: 34157104 PMC: 8530718. DOI: 10.1210/clinem/dgab461.

References

Pearlman M, Griffin J . Benign breast disease. Obstet Gynecol. 2010; 116(3):747-758. DOI: 10.1097/AOG.0b013e3181ee9fc7. View

Barnes B, Chang-Claude J, Flesch-Janys D, Kinscherf R, Schmidt M, Slanger T . Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. Cancer Causes Control. 2009; 20(10):1985-96. DOI: 10.1007/s10552-009-9393-0. View

Ernster V, Wrensch M, PETRAKIS N, King E, Miike R, Murai J . Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst. 1987; 79(5):949-60. View

Key T, Appleby P, Barnes I, Reeves G . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94(8):606-16. DOI: 10.1093/jnci/94.8.606. View

Rohan T, Negassa A, Chlebowski R, Habel L, McTiernan A, Ginsberg M . Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008; 100(8):563-71. DOI: 10.1093/jnci/djn075. View

Rice M, Tamimi R, Connolly J, Collins L, Shen D, Pollak M . Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. Breast Cancer Res. 2012; 14(2):R44. PMC: 3446378. DOI: 10.1186/bcr3141. View

Dupont W, Page D . Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312(3):146-51. DOI: 10.1056/NEJM198501173120303. View

Key T, Appleby P, Reeves G, Roddam A . Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010; 11(6):530-42. PMC: 3113287. DOI: 10.1016/S1470-2045(10)70095-4. View

Parlati E, Travaglini A, Liberale I, Menini E, DellAcqua S . Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988; 11(9):679-83. DOI: 10.1007/BF03350214. View

10.

Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P . Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979; 53(4):457-60. View

11.

Singer C, Mogg M, Koestler W, Pacher M, Marton E, Kubista E . Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res. 2004; 10(12 Pt 1):4003-9. DOI: 10.1158/1078-0432.CCR-03-0093. View

12.

James R, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A . Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila). 2011; 4(10):1626-35. DOI: 10.1158/1940-6207.CAPR-11-0090. View

13.

Mancini A, Di Pietro C, De Marinis L, Rossi S, Lombardi C, Iacona T . Endocrine evaluation of patients with benign lumps of the breast. Cancer Detect Prev. 1992; 16(1):27-30. View

14.

Holdaway I, Mason B, Lethaby A, Singh V, Harman J, MacCormick M . Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust N Z J Surg. 1999; 69(7):495-500. DOI: 10.1046/j.1440-1622.1999.01610.x. View

15.

Shekhar M, Nangia-Makker P, WOLMAN S, Tait L, Heppner G, Visscher D . Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Am J Pathol. 1998; 152(5):1129-32. PMC: 1858583. View

16.

Eliassen A, Missmer S, Tworoger S, Spiegelman D, Barbieri R, Dowsett M . Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006; 98(19):1406-15. DOI: 10.1093/jnci/djj376. View

17.

Mancini A, Di Pietro C, De Marinis L, Rossi S, Lombardi C, Bellantone R . Endocrine status in patients with mammary gland diseases: correlation between steroid hormones and sex steroid binding globulin. Gynecol Endocrinol. 1991; 5(2):101-8. DOI: 10.3109/09513599109028433. View

18.

Reed M, Cheng R, Noel C, Dudley H, James V . Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res. 1983; 43(8):3940-3. View

19.

Langley M, Hammond G, Bardsley A, SELLWOOD R, Anderson D . Serum steroid binding proteins and the bioavailability of estradiol in relation to breast diseases. J Natl Cancer Inst. 1985; 75(5):823-9. DOI: 10.1093/jnci/75.5.823. View

20.

Su X, Colditz G, Willett W, Collins L, Schnitt S, Connolly J . Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer. 2009; 126(1):180-90. PMC: 2783930. DOI: 10.1002/ijc.24674. View